Latest Strategic Review News

Eagle Mountain Mining has strengthened its Silver Mountain copper project prospects, initiated tailings repurposing at Wedgetail, and launched a capital raise to reduce debt, while relinquishing Oracle Ridge mineral rights due to unaligned landowner terms.

Kingston Resources delivered robust production and revenue growth at Mineral Hill in Q4 2024, while advancing a strategic review of its Misima Gold Project to unlock further value.

Locksley Resources reports standout assay results from its Mojave Project alongside strategic board appointments and a comprehensive review of its Tottenham Copper Project, setting the stage for accelerated exploration and resource development.

Moho Resources has completed the sale of its East Sampson Gold Project for up to $4 million and raised $673,000 through a share placement, marking a strategic pivot to optimise its portfolio and fund exploration.

Ecofibre Limited reports a mixed financial performance for Q2 2025, highlighting significant debt reduction efforts and strategic restructuring to return to positive cash flows.

Adslot Ltd reports a robust Q2 FY25 with significant contract wins for its StoreFront platform and a 43% quarter-on-quarter increase in monetised transaction value, despite ongoing challenges in the Australian market.

Codeifai Limited reports a sharp 59% reduction in quarterly cash burn alongside a 48% rise in cash receipts, driven by its new ConnectQR SaaS platform and a strategic review of its Material Science division.

Metal Bank Limited reports significant progress across its Australian and MENA projects, including a strategic review of its Livingstone Gold Project and new exploration rights in Saudi Arabia and Jordan, supported by a fully subscribed $1.56 million entitlement offer.

Bastion Minerals has completed its acquisition of three high-grade Canadian copper projects and raised AUD$1 million to fund exploration, positioning itself as a growing player in the energy transition metals sector.

AdAlta Limited has bolstered its leadership team and progressed its 'East to West' cellular therapy strategy alongside its lead drug candidate AD-214, despite a tightening cash position. The company’s recent non-binding term sheet and new clinical data signal promising momentum in its biotech pipeline.

Percheron Therapeutics has terminated its phase IIb avicursen trial for Duchenne muscular dystrophy after failing to meet efficacy endpoints, while securing $14.85 million in fresh capital to explore new therapeutic opportunities.

Pro-Pac Packaging reported a revenue increase to $73.1 million for Q2 FY25, supported by new financing facilities and a fresh CEO appointment, while navigating cash flow pressures and challenging market conditions.